July 31, 2023

The STATICE Trial with Tadaaki Nishikawa

20 minutes

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Tadaaki Nishikawa to discuss the STATICE trial. Dr. Nishikawa worked as a gynecological oncologist for half his career and is currently working as a medical oncologist at National Cancer Center Japan. He focuses on developing new agents for GY cancers.

Highlights:

Trastuzumab deruxtecan demonstrated clinical activity in previously treated patients with advanced or recurrent uterine carcinosarcoma regardless of HER2 status in the STATICE trial.

The overall response rates were 54.5% in the HER2-high (2+ or 3+) cohort and 70% in the HER2-low (1+) cohort, respectively.

Adverse events ≥ grade 3 occurred in 61% of patients and pneumonitis or interstitial lung disease of grades 1-2 and 3 occurred in 24% and 3% of patients, respectively.

We performed a co-clinical study of trastuzumab deruxtecan using patient-derived xenograft models of participants in the STATICE trial.

Tumor shrinkage after trastuzumab deruxtecan administration was observed in PDX models, which included two patients enrolled in the STATICE trial.

...more

View all episodes

By BMJ Group

2323 ratings